We are offering free-of-charge access to the PDX models, resources, and expertise of the EurOPDX Research Infrastructure (EurOPDX RI), as part of the EU-funded EDIReX project. Known as Trans-national Access (TA) grants, we welcome proposals in two forms:
1) SAMPLE – where researchers can request PDX models for their research from our newly developed EurOPDX Data Portal. Then, if selected, they would receive aliquots of a PDX model that has been engrafted and grown in NSG mice, quality controlled according to the high standards of EurOPDX, and delivered alongside its PDX passport containing all important accompanying information.
2) DEPOSIT – where researchers can request the deposition of their own PDX models within our distributed EurOPDX RI biobank, and displayed within our newly developed public repository, the EurOPDX Data Portal. Proposals that are selected for this type of access grant will have their PDX model health-checked, engrafted and grown in NSG mice by one of the EurOPDX RI node institutes, aliquoted, quality controlled according to the high standards of EurOPDX, then biobanked with the EurOPDX RI and displayed within the EurOPDX Data Portal for increased visibility to facilitate its further use by the wider research community.
Both forms of access will be provided free-of-charge to successful applicants, excluding final material shipment costs.
The 1st call for proposals for both types of access opened on the October 31st 2018, and the deadline for proposal submission is January 31st 2019, 17:00 CEST.
For full information on this call for proposals, please visit: www.europdx.eu/europdxri-ta and download our “Guide for Applicants” and “Application forms”.
For any questions regarding the EurOPDX Research Infrastructure Trans-national Access programme, please contact our helpdesk at: firstname.lastname@example.org
There will also be two further calls for proposals as part of the EDIReX project – The 2nd and 3rd calls for access will open in October 2019 and Spring 2020 respectively.
From the 2nd call, “TEST” access will also be available – which will include the performance of in vivo preclinical experiments on PDXs engrafted in immunocompromised mice.